XOMA to Present at the UBS Global Healthcare Conference
15 Mai 2018 - 1:00PM
XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery,
development and licensing of therapeutic antibodies, today
announced that Jim Neal, Chief Executive Officer, will present the
Company’s royalty-aggregator business model at the UBS Global
Healthcare Conference on Tuesday, May 22, 2018, at 1:00 p.m. ET.
The conference is being held in New York City.
A live audio webcast of the presentation can be accessed in the
Investors section of XOMA's website at www.xoma.com. An archived
version of the webcast will be available via replay for 90 days
following the presentation.
About XOMA Corporation
XOMA has built a portfolio of over two dozen products that are
licensed to and being developed by other biotech and pharmaceutical
companies. The Company’s portfolio of partner-funded programs spans
multiple stages of the drug development process and across various
therapeutic areas. Many of these licenses are the result of XOMA’s
pioneering efforts in the discovery and development of antibody
therapeutics. The Company’s royalty-aggregator business model
includes acquiring additional licenses to partner-funded programs.
XOMA’s license portfolio has the potential to generate significant
milestone payments and royalty revenue in the future. For more
information, visit www.xoma.com.
Forward-Looking Statements
Certain statements contained in this press release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, including statements regarding the potential of XOMA’s
portfolio of partnered programs and licensed technologies
generating substantial milestone and royalty proceeds over time.
These statements are based on assumptions that may not prove
accurate, and actual results could differ materially from those
anticipated due to certain risks inherent in the biotechnology
industry, including those related to the fact that our product
candidates subject to out-license agreements are still being
developed, and our licensees’ may require substantial funds to
continue development which may not be available; we do not know
whether there will be, or will continue to be, a viable market for
the products in which we have an ownership or royalty interest; we
may not be successful in entering into out-license agreements for
our product candidates; if our therapeutic product candidates do
not receive regulatory approval, our third-party licensees will not
be able to manufacture and market them. Other potential risks to
XOMA meeting these expectations are described in more detail in
XOMA's most recent filing on Form 10-K and in other SEC filings.
Consider such risks carefully when considering XOMA's prospects.
Any forward-looking statement in this press release represents
XOMA's views only as of the date of this press release and should
not be relied upon as representing its views as of any subsequent
date. XOMA disclaims any obligation to update any forward-looking
statement, except as required by applicable law.
Investor contact:Luke HeagleW2O
pure+1 910-726-1372lheagle@w2ogroup.com
Media contact:Julie NormartW2O
pure+1 415-946-1087jnormart@w2ogroup.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
Von Apr 2023 bis Apr 2024